Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells

Molecular Therapy

Volumn 25, Issue 1, 2017, Pages 259-273

  Whilding, Lynsey M ^a   Parente Pereira, Ana C ^a   Zabinski, Tomasz ^a   Davies, David M ^a   Petrovic, Roseanna M G ^a   Kao, Y Vincent ^a   Saxena, Shobhit A ^a   Romain, Alex ^a   Costa Guerra, Jose A ^a   Violette, Shelia ^b   Itamochi, Hiroaki ^c   Ghaem Maghami, Sadaf ^d   Vallath, Sabari ^e   Marshall, John F ^e   Maher, John ^a,f,g  

^a GUY S HOSPITAL   (United Kingdom)

^b BIOGEN   (United States)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

cancer; chimeric antigen receptor; Immunotherapy; solid tumor; v 6

Indexed keywords

ALPHAVBETA6 INTEGRIN; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 4; PEPTIDE A20; UNCLASSIFIED DRUG; VIRAL PROTEIN; CYTOKINE; HYBRID PROTEIN; INTEGRIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; FOOT AND MOUTH DISEASE VIRUS; FUSION GENE; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; SCID BEIGE MOUSE; SOLID TUMOR; T LYMPHOCYTE; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG SCREENING; GENE ORDER; GENE VECTOR; GENETICS; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; NEOPLASMS; SCID MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; CELL ENGINEERING; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; IMMUNOTHERAPY, ADOPTIVE; INTEGRINS; LYMPHOCYTE SUBSETS; MICE; MICE, SCID; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016322535     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2016.10.012     Document Type: Article

References (45)

1. 1 Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 2014, 224ra25.
2. 2 Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
3. 3 Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P., Carpenter, R.O., Stetler-Stevenson, M., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33 (2015), 540–549.
4. 4 Morgan, R.A., Johnson, L.A., Davis, J.L., Zheng, Z., Woolard, K.D., Reap, E.A., Feldman, S.A., Chinnasamy, N., Kuan, C.T., Song, H., et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23 (2012), 1043–1053.
5. 5 Johnson, L.A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P.R., McGettigan, S.E., Nace, A.K., Dentchev, T., Thekkat, P., Loew, A., et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med., 7, 2015, 275ra22.
6. 6 Del Vecchio, C.A., Giacomini, C.P., Vogel, H., Jensen, K.C., Florio, T., Merlo, A., Pollack, J.R., Wong, A.J., EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene 32 (2013), 2670–2681.
7. 7 Montano, N., Cenci, T., Martini, M., D'Alessandris, Q.G., Pelacchi, F., Ricci-Vitiani, L., Maira, G., De Maria, R., Larocca, L.M., Pallini, R., Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia 13 (2011), 1113–1121.
8. 8 Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 (2010), 843–851.
9. 9 Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33 (2015), 1688–1696.
10. 10 Hynes, R.O., Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002), 673–687.
11. 11 Van Aarsen, L.A., Leone, D.R., Ho, S., Dolinski, B.M., McCoon, P.E., LePage, D.J., Kelly, R., Heaney, G., Rayhorn, P., Reid, C., et al. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res. 68 (2008), 561–570.
12. 12 Hazelbag, S., Kenter, G.G., Gorter, A., Dreef, E.J., Koopman, L.A., Violette, S.M., Weinreb, P.H., Fleuren, G.J., Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212 (2007), 316–324.
13. 13 Elayadi, A.N., Samli, K.N., Prudkin, L., Liu, Y.H., Bian, A., Xie, X.J., Wistuba, I.I., Roth, J.A., McGuire, M.J., Brown, K.C., A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 67 (2007), 5889–5895.
14. 14 Moore, K.M., Thomas, G.J., Duffy, S.W., Warwick, J., Gabe, R., Chou, P., Ellis, I.O., Green, A.R., Haider, S., Brouilette, K., et al. Therapeutic targeting of integrin αvβ6 in breast cancer. J. Natl. Cancer Inst., 106, 2014, dju169.
15. 15 Ahmed, N., Riley, C., Rice, G.E., Quinn, M.A., Baker, M.S., Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J. Histochem. Cytochem. 50 (2002), 1371–1380.
16. 16 Sipos, B., Hahn, D., Carceller, A., Piulats, J., Hedderich, J., Kalthoff, H., Goodman, S.L., Kosmahl, M., Klöppel, G., Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 45 (2004), 226–236.
17. 17 Thomas, G.J., Nyström, M.L., Marshall, J.F., Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J. Oral Pathol. Med. 35 (2006), 1–10.
18. 18 Bates, R.C., Bellovin, D.I., Brown, C., Maynard, E., Wu, B., Kawakatsu, H., Sheppard, D., Oettgen, P., Mercurio, A.M., Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 115 (2005), 339–347.
19. 19 Thomas, G.J., Lewis, M.P., Whawell, S.A., Russell, A., Sheppard, D., Hart, I.R., Speight, P.M., Marshall, J.F., Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J. Invest. Dermatol. 117 (2001), 67–73.
20. 20 Thomas, G.J., Lewis, M.P., Hart, I.R., Marshall, J.F., Speight, P.M., AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int. J. Cancer 92 (2001), 641–650.
21. 21 Morgan, M.R., Thomas, G.J., Russell, A., Hart, I.R., Marshall, J.F., The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J. Biol. Chem. 279 (2004), 26533–26539.
22. 22 Breuss, J.M., Gallo, J., DeLisser, H.M., Klimanskaya, I.V., Folkesson, H.G., Pittet, J.F., Nishimura, S.L., Aldape, K., Landers, D.V., Carpenter, W., et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 108 (1995), 2241–2251.
23. 23 Eberlein, C., Kendrew, J., McDaid, K., Alfred, A., Kang, J.S., Jacobs, V.N., Ross, S.J., Rooney, C., Smith, N.R., Rinkenberger, J., et al. A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene 32 (2013), 4406–4416.
24. 24 Kogelberg, H., Tolner, B., Thomas, G.J., Di Cara, D., Minogue, S., Ramesh, B., Sodha, S., Marsh, D., Lowdell, M.W., Meyer, T., et al. Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus. J. Mol. Biol. 382 (2008), 385–401.
25. 25 Burman, A., Clark, S., Abrescia, N.G., Fry, E.E., Stuart, D.I., Jackson, T., Specificity of the VP1 GH loop of Foot-and-Mouth Disease virus for alphav integrins. J. Virol. 80 (2006), 9798–9810.
26. 26 DiCara, D., Rapisarda, C., Sutcliffe, J.L., Violette, S.M., Weinreb, P.H., Hart, I.R., Howard, M.J., Marshall, J.F., Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J. Biol. Chem. 282 (2007), 9657–9665.
27. 27 Hausner, S.H., DiCara, D., Marik, J., Marshall, J.F., Sutcliffe, J.L., Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res. 67 (2007), 7833–7840.
28. 28 Saha, A., Ellison, D., Thomas, G.J., Vallath, S., Mather, S.J., Hart, I.R., Marshall, J.F., High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. J. Pathol. 222 (2010), 52–63.
29. 29 Kraft, S., Diefenbach, B., Mehta, R., Jonczyk, A., Luckenbach, G.A., Goodman, S.L., Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J. Biol. Chem. 274 (1999), 1979–1985.
30. 30 Maher, J., Brentjens, R.J., Gunset, G., Rivière, I., Sadelain, M., Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20 (2002), 70–75.
31. 31 Wilkie, S., Burbridge, S.E., Chiapero-Stanke, L., Pereira, A.C., Cleary, S., van der Stegen, S.J., Spicer, J.F., Davies, D.M., Maher, J., Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285 (2010), 25538–25544.
32. 32 Parente-Pereira, A.C., Whilding, L.M., Brewig, N., van der Stegen, S.J., Davies, D.M., Wilkie, S., van Schalkwyk, M.C., Ghaem-Maghami, S., Maher, J., Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin. J. Immunol. 191 (2013), 2437–2445.
33. 33 van der Stegen, S.J., Davies, D.M., Wilkie, S., Foster, J., Sosabowski, J.K., Burnet, J., Whilding, L.M., Petrovic, R.M., Ghaem-Maghami, S., Mather, S., et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?. J. Immunol. 191 (2013), 4589–4598.
34. 34 Parente-Pereira, A.C., Burnet, J., Ellison, D., Foster, J., Davies, D.M., van der Stegen, S., Burbridge, S., Chiapero-Stanke, L., Wilkie, S., Mather, S., Maher, J., Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 31 (2011), 710–718.
35. 35 Pameijer, C.R., Navanjo, A., Meechoovet, B., Wagner, J.R., Aguilar, B., Wright, C.L., Chang, W.C., Brown, C.E., Jensen, M.C., Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther. 14 (2007), 91–97.
36. 36 van Schalkwyk, M.C., Papa, S.E., Jeannon, J.P., Guerrero Urbano, T., Spicer, J.F., Maher, J., Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum. Gene Ther. Clin. Dev. 24 (2013), 134–142.
37. 37 Maude, S.L., Barrett, D., Teachey, D.T., Grupp, S.A., Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20 (2014), 119–122.
38. 38 Salguero, F.J., Sánchez-Martín, M.A., Díaz-San Segundo, F., de Avila, A., Sevilla, N., Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. Virology 332 (2005), 384–396.
39. 39 Prempeh, H., Smith, R., Müller, B., Foot and mouth disease: the human consequences. The health consequences are slight, the economic ones huge. BMJ 322 (2001), 565–566.
40. 40 Davies, D.M., Foster, J., Van Der Stegen, S.J., Parente-Pereira, A.C., Chiapero-Stanke, L., Delinassios, G.J., Burbridge, S.E., Kao, V., Liu, Z., Bosshard-Carter, L., et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol. Med. 18 (2012), 565–576.
41. 41 Bendtsen, J.D., Nielsen, H., von Heijne, G., Brunak, S., Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 340 (2004), 783–795.
42. 42 Logan, D., Abu-Ghazaleh, R., Blakemore, W., Curry, S., Jackson, T., King, A., Lea, S., Lewis, R., Newman, J., Parry, N., et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 362 (1993), 566–568.
43. 43 Loening, A.M., Wu, A.M., Gambhir, S.S., Red-shifted Renilla reniformis luciferase variants for imaging in living subjects. Nat. Methods 4 (2007), 641–643.
44. 44 Parente-Pereira, A.C., Wilkie, S., van der Stegen, S., Davies, D.M., Maher, J., Use of retroviral-mediated gene transfer to deliver and test function of chimeric antigen receptors in human T-cells. J. Biol. Methods, 1, 2014, e7.
45. 45 Weinreb, P.H., Simon, K.J., Rayhorn, P., Yang, W.J., Leone, D.R., Dolinski, B.M., Pearse, B.R., Yokota, Y., Kawakatsu, H., Atakilit, A., et al. Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. J. Biol. Chem. 279 (2004), 17875–17887.